Letters sent to healthcare professionals in April 2016
In April 2016, letters were sent regarding canagliflozin (Invokana▼, Vokanamet▼), BCR-ABL tyrosine kinase inhibitors, pomalidomide (Imnovid▼), and retigabine (Trobalt)
Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials
There are new interim treatment recommendations for idelalisib for chronic lymphocytic leukaemia and follicular lymphoma in light of new findings from clinical trials outside its currently authorised drug combinations or indicated populations.
Pomalidomide (Imnovid▼): risk of hepatitis B reactivation
Before starting treatment with pomalidomide, establish hepatitis B virus status in all patients.
BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
Patients should be tested for hepatitis B virus before starting treatment with BCR-ABL tyrosine kinase inhibitors.